Translate

CORONAVIRUS COVID-19 Global Cases by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU) ...

domingo, 8 de octubre de 2017

Se valida una nueva escala para evaluar la calidad de vida en pacientes pediátricos con epilepsia


Abstract

INTRODUCTION: 
Epilepsy has a high impact on the quality of life of the child, so it is important to have validated and consistent instruments to evaluate it.

AIM: 

To compare the validity and reliability of a new quality of life scale for paediatric epileptic patients (ECAVIPEP) from a Mexican hospital against the widely validated CAVE scale.

PATIENTS AND METHODS: 

A comparative study was conducted to test the validity and realiability of a new scale for evaluating epilepsy in children. The test, conducted on a sample of epileptic children between 4 and 10 years of age, involved the application of a new quality of life scale and comparing it with the widely validated CAVE scale. Cronbach's alpha and Spearman's rho were used for validity and consistency.

RESULTS: 

There were 114 patients, 72 (63.2%) male and 42 (36.8%) female. Internal consistency yielded a Cronbach's alpha value of 0.673. For the analysis of convergent validity, scores obtained by CAVE and ECAVIPEP Spearman's rho correlation was 0.670 (p lower than 0).

CONCLUSIONS: 

ECAVIPEP scale is valid and consistent to assess epilepsy in children from 4 to 10 years.

No hay comentarios:

Publicar un comentario

Aportes